ArticleThe American journal of pathology1997
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
Article in The American journal of pathology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 113 citations in OpenAlex.
- Role of Transcription Factor Fli-1 in Inflammation and Autoimmune Diseases.Biomolecules · 2025Review
- Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα.Blood advances · 2021Article
- IL-6 in inflammation, autoimmunity and cancer.International immunology · 2021Review
- Article
- Review
- Review
- Activated Natural Killer Cells Mediate the Suppressive Effect of Interleukin-4 on Tumor Development via STAT6 Activation in an Atopic Condition Melanoma Model.Neoplasia (New York, N.Y.) · 2017Article
- Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.Journal of virology · 2016Article
- Article
- Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.Clinical and experimental immunology · 2015Article
- IL-6 as a keystone cytokine in health and disease.Nature immunology · 2015Review
- Increased NHC Cells in the Peritoneal Cavity of Plasmacytoma Susceptible BALB/c Mouse.Mediators of inflammation · 2015Article
- The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.Leukemia · 2015Article
- The class-specific BCR tonic signal modulates lymphomagenesis in a c-myc deregulation transgenic model.Oncotarget · 2014Article
- Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.Immunologic research · 2014Review
- Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.ISRN hematology · 2013Review
- Therapeutic effect of Withania somnifera on pristane-induced model of SLE.Inflammopharmacology · 2012Article
- Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells.RNA biology · 2012Article
- Hematologic neoplasias and acromegaly.Pituitary · 2011Article
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.The Journal of clinical investigation · 2011Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-6 is known to be an essential growth factor for myeloma cells, both in vitro and in vivo. In mice, IL-6 is required for development of B cell tumors upon infection with a retrovirus expressing the myc/raf oncogenes. In the present study, we used the pristane-oil-induced plasmacytoma model, which more closely mimics tumor transformation and progression in human multiple myeloma. Also using this system, we found that IL-6-deficient BALB/c mice are protected against tumor development. Although the pristane-induced inflammatory reaction was less pronounced in IL-6-deficient mice versus their wild-type littermates, both B cell differentiation and plasma cell formation took place, and even morphological evidence of plasma cell transformation was detected, albeit at a low frequency. However, in the absence of IL-6, there were never signs of uncontrolled proliferation of either normal B lymphocytes or tumor cells, suggesting that the role of IL-6 in murine plasmacytoma and possibly also in human multiple myeloma is to ensure abnormal survival and proliferation of previously transformed tumor cells and therefore tumor development and progression.
Indexed as
Identifiers
9284817PMC1857831W1513968969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.